<DOC>
	<DOCNO>NCT01262872</DOCNO>
	<brief_summary>This study assess impact nasopharyngeal carriage , safety immunogenicity GSK Biologicals ' pneumococcal vaccine 2189242A give 3-dose vaccination course co-administered routine paediatric vaccine infants The Gambia . Two formulation contain different dos pneumococcal antigen two different schedule test infant .</brief_summary>
	<brief_title>Impact GSK Biologicals ' 2189242A Vaccine Nasopharyngeal Carriage , Safety &amp; Immunogenicity Children &amp; Infants</brief_title>
	<detailed_description>There two cohort study : Cohort 1 ( child age 2-4 year ) Cohort 2 ( infant age 8-10 week ) , two step study , Step 1 Step 2 . Step 1 consist safety evaluation GSK Biologicals ' pneumococcal vaccine 2189242A ( GSK 2189242A 10PP vaccine ) . Before evaluate two formulation 10PP vaccine infant ( Cohort 2 ) , safety reactogenicity high dose formulation vaccine evaluate child ( Cohort 1 ) . Prevnar 13™ use control . In second step study , Step 2 , two investigational formulation 10PP vaccine test infant ( Cohort 2 ) regard immunogenicity , reactogenicity safety . Both formulation 10PP vaccine evaluate accord Expanded Programme Immunization ( EPI ) schedule i.e . 2 , 3 , 4 month vaccination schedule , use license Synflorix™ Prevnar 13™ vaccine comparators . The high dose ( HD ) formulation 10PP vaccine also evaluate accord 2 , 4 , 9 month vaccination schedule use licensed Synflorix™ vaccine comparator . The study infant also assess immune response routine vaccine co-administered candidate pneumococcal vaccine , use license Synflorix™ Prevnar 13™ vaccine comparators .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion subject Cohort 1 ( child ) Cohort 2 ( infant ) : Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol Male female , include , 2 4 year age time first vaccination subject Cohort 1 ( child ) . 8 10 week ( 5676 day ) age time first vaccination subject Cohort 2 ( infant ) . Signed thumbprinted informed consent obtain parents/LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Permanent residence study area intention leave study period . Additional inclusion criterion subject Cohort 1 : • Previously complete threedose primary course diphtheriatetanuspertussis ( DTP ) vaccination . Exclusion criterion subject Cohort 1 ( child ) Cohort 2 ( infant ) : Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol study period start 30 day dose end 30 day dose vaccine ( ) , exception license flu vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Previous vaccination S. pneumoniae . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Malnutrition A family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect chronic illness . History neurologic disorder seizure . Acute disease and/or fever time enrolment . Administration immunoglobulins and/ blood product within 3 month precede first dose study vaccine plan administration study period . Contraindications coadministered vaccine . Any medical condition would contraindicate initiation routine immunization outside clinical trial context . Additional exclusion criterion subject Cohort 1 : • Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b exception vaccine first dose give within first two week life accord national recommendation ( example Bacillus CalmetteGuérin [ BCG ] hepatitis B vaccination ) .</criteria>
	<gender>All</gender>
	<minimum_age>56 Days</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>The Gambia</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>nasopharyngeal carriage</keyword>
	<keyword>infant</keyword>
	<keyword>safety</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>child</keyword>
</DOC>